Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: bob zagorin who wrote (20709)	5/13/1998 7:50:00 PM
From: Machaon	Respond to of 32384

<< ... my guess, mild accumulation but no dramatic reaction to the acqusition of the H&Q revision. >> Sounds ok to me. To me, the acquisition just adds fuel to the fire. I like the action on LGND over the last couple of weeks. I'm hoping that we are going to get a spring/summer rally for the 4th year in a row. (hope, hope, hope!) What do you think? We have two NDA's on the fire, and an earnings report coming out? And, biotech is currently in the spotlight, what with Viagra, and Cancer, and Flu Sprays. Will this year be different than the last three, resulting in no LGND rally? If Santa Claus has been reading this thread, he might not think that anyone deserves a pre-xmas, spring/summer LGND rally again! (Except for Henry, who does most of the work). Hmmmm!? But, then again, Henry might not believe in Santa! Good luck, Bob

To: bob zagorin who wrote (20709)	5/13/1998 8:50:00 PM
From: Machaon	Read Replies (1) \| Respond to of 32384

Bob, did you see what happened to MOGN today? It went from $8 to $24, and then pulled back to $12+, because the president of MOGN announced that they are hopeful about their cancer drug, now in Phase I testing. You know what that means to me!? HYPE!!! I WANT SOME LGND HYPE!!!!! LGND, HYPE ME! SOCK IT TO ME WITH HYPE! HYPEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEE!!!!!!!!!!!!!!!!!!!!!!!! Sorry, I got carried away. I've got a portfolio mostly full of biotech. With these nutsy skyrockets, whenever cancer drugs are hyped, who knows what will be next. Investors could start getting the itch and may start increasing their biotech holdings. Right? Good luck, Bob